Summary & Overview
HCPCS Level II J9034: Injection, bendamustine HCl (Bendeka), 1 mg
HCPCS Level II code J9034 denotes the injectable chemotherapy agent bendamustine hydrochloride (Bendeka), billed per milligram. The code captures a widely used antineoplastic medication for hematologic malignancies and other oncology indications where bendamustine is clinically appropriate. Nationally, accurate coding for high-cost oncology drugs like bendamustine is critical for claims processing, clinical documentation, and cost management in outpatient infusion settings.
Key payers included in the coverage analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what the code represents, typical sites of service, and the clinical context for use. The publication summarizes available benchmarks and policy considerations relevant to billing and reimbursement for injectable chemotherapy agents, highlights common payer coverage patterns, and outlines coding details and documentation elements that commonly affect claim adjudication.
The report is designed to inform billing leads, oncology practice managers, and revenue cycle professionals about how J9034 is used on service lines, where variations commonly occur, and which operational and policy factors influence payment. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J9034 represents the injection of bendamustine hydrochloride (Bendeka), 1 mg. This code is used to bill for the drug product by milligram when administered as an injectable chemotherapy or antineoplastic agent.
Service type: Medication administration — injectable antineoplastic (chemotherapy) agent
Typical site of service: Outpatient infusion center or hospital outpatient department; may also be used in physician office settings that provide chemotherapy infusions.
Data not available in the input for additional fields.
Clinical & Coding Specifications
Clinical Context
A 65-year-old patient with relapsed indolent non-Hodgkin lymphoma presents to an outpatient oncology infusion center for chemotherapy. The oncologist prescribes bendamustine hydrochloride (Bendeka) delivered intravenously as part of a combination regimen. The patient arrives for a scheduled infusion after pre-visit nursing assessment confirms recent labs (CBC, CMP) within acceptable parameters and that premedications (antiemetic and antihistamine if indicated) have been administered. The oncology nurse verifies orders, obtains venous access via peripheral IV or implanted port, prepares weight-based dosing, and documents lot number and vial usage. The pharmacist compounds the dose in an appropriate sterile environment, labels the syringe or bag and communicates infusion start time. During infusion, nursing monitors vital signs, infusion tolerance, and documents any acute reactions; dose modifications or infusion interruptions are captured with appropriate modifier reporting. After completion, the nurse records total mg administered, disposes of hazardous waste per protocol, and schedules follow-up visits for toxicity assessment and next-cycle planning.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Use when no other applicable modifier is reported for the service |
11 |